AxsomeAXSM
NASDAQ制药
US$206.00-4.19%
关键指标
$9.36B市值
US$193.4952 周最高
US$96.0952 周最低
601,16330 日均量
925 员工数51.15M 流通股本上市日期 2015-11-19
下次财报 ~2026年5月5日
关于 Axsome
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
最新新闻
展示全市场股票新闻
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Nifty holds above 23,250 level; European shares trade mostly in green
Stock futures mixed as Fed rate decision takes center stage
Macro Uncertainty Fuels Hedging Demand Ahead Of FOMC
Dow Jones futures tick higher ahead of Fed interest rate decision
Markets await the FOMC decision
相关股票制药 行业
想看 AXSM 的实时 AI 观点?
启动实时多智能体分析室 — Claude、GPT、Gemini、DeepSeek、Grok 和 Qwen 同时分析 AXSM,实时输出信号。